Sattari said on Sunday that a foreign company had deliberately reduced prices for an anti-hemophilic medicine known as Factor VIII
in order to prevent an Iranian company to sell the drug to patients inside the country.
* Long-term follow-up from four phase III studies (HAVEN studies) shows Hemlibra's sustained efficacy and safety in people with hemophilia A, with and without factor VIII
- US-based biotechnology company Genentech, a member of Switzerland's Roche Group (SIX: RO) (OTCQX: RHHBY), has presented new data for Hemlibra (emicizumab-kxwh) across multiple pivotal studies in people with hemophilia A with and without factor VIII
inhibitors at the International Society on Thrombosis and Haemostasis 2019 Congress on July 6-10 in Melbourne, Australia, the company said.
Roche announced new data for Hemlibra (emicizumab) across multiple pivotal studies in people with haemophilia A with and without factor VIII
inhibitors at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress on 6-10 July in Melbourne, Australia.
Substantial Reduction in excess of 92% in Mean Bleed Rate Requiring Factor VIII
Infusions; Sustained over the Period of Observation (3 Years in High Dose and 2 Years in Low Dose)
As of May 28, 2019, eight patients in the 20-patient cohort of the Phase 3 GENEr8-1 study achieved Factor VIII
levels of 40 international units per deciliter, or IU/dL, or more, at 23 to 26 weeks, meeting the pre-specified criteria for Factor VIII
Reportedly, the CHMP recommends Esperoct, the brand name for turoctocog alfa pegol, N8-GP, to be indicated for prophylaxis and on-demand treatment of bleeding as well as for surgical procedures in adolescents (>=12 years of age) and adults with haemophilia A (congenital factor VIII
Objective: To determine the frequency and levels of factor VIII
inhibitors in known haemophilics in our population.
29, 2018 (HealthDay News) -- For patients with hemophilia A without factor VIII
inhibitors, emicizumab prophylaxis leads to a significantly reduced bleeding rate, according to a study published in the Aug.
NORDIC BUSINESS REPORT-February 28, 2018-Novo Nordisk files for regulatory approval of long-acting factor VIII
(N8-GP) in US and EU
The treatment of hemophilia may involve prophylaxis, management of bleeding episodes, treatment of factor VIII
(FVIII) inhibitors, and treatment and rehabilitation of hemophilia synovitis.
Haemophilia is a rare condition where patients present with abnormal bleeding and other complications of bleeding due to genetic or acquired deficiency of coagulation factor VIII
(Haemophilia A) or factor IX (Haemophilia B).